2025 General Assembly: a new impetus for IML
“Innovation is not a slogan, it is a responsibility.”
Romain Labé
On June 3, IML held its annual general meeting at the Robert Schuman Hospitals in Luxembourg, attended by members and around 30 guests. It was an opportunity to review the collective's significant progress and the new momentum generated by IML.
“Innovation is not a slogan, it is a responsibility.” This is how Romain Labé, Secretary General of IML, concluded his speech during the statutory part of the General Meeting. An approach shared by most of the members, guests, and speakers present.
Innovation is a term that appears in all brochures, political speeches, annual reports, etc. It is too often used, poorly explained, overused, or used as a catch-all term that is difficult to define.
For IML members, innovation is first and foremost about research and the development of new drugs and pharmaceutical products that improve patients' lives and give hope to those who struggle every day with a condition that weighs heavily on their daily lives. For our association, which represents these industries, innovation also means giving them the means to make their voices heard by the authorities who authorize these advances. It is a mindset that lies somewhere between scientific reality and large-scale awareness, the need for transparency, the desire for agility, and the opportunity to share.
The healthcare ecosystem of tomorrow
How should healthcare data be used? How can AI and research be reconciled? AI and therapeutic protocols for patients? How can we work with national authorities to build a resilient, agile, and transparent healthcare ecosystem? These were the topics discussed during the round table organized by IML in the second part of the General Assembly.
A big thank you to the guests: Dr. Anna Chioti, Dr. Jos Even, Daniel Theisen, and Rick Schneider, who outlined a “dream” innovation within reach of projects!
IML also thanks Dr. Marc Berna for his welcome at the Robert Schuman Hospitals, and Gregory Willocq for his incredible talent as an insightful interviewer.
The members unanimously elected the four candidates whose terms were up for renewal on the Board of Directors: Grégory Willocq (Abbvie), Bart Croes (Bristol Myers Squibb), Jean-Michel Luyckx (Novartis), and Peter Van Herck (Bayer). Two new companies also joined IML: Laboratoires Khôl and CSL Behring, bringing the number of members to 65.
Keep up to date with iml.lu
The flash letter informs you regularlay about the news of our sector in Luxembourg, the news of the research in Luxembourg, within our members and finally about the news of the association. Don't waste a minute and subscribe.